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Abstract
Purpose of This Review The implantation of a left ventricular assist device (LVAD) is associated with high hemorrhage-related
re-exploration rates. Improved management of coagulopathy may improve patient outcome. The optimal management of ac-
quired coagulopathy in LVAD patients needing urgent non-cardiac surgery needs to be defined.We aim to review risk factors for
perioperative bleeding and diagnosis and management of LVAD-associated coagulopathy and to provide expert recommenda-
tions for clinical practice.
Recent Findings In patients undergoing LVAD implantation, the severity of coagulopathy is directly related to the severity of the
cardiac failure. The evidence from current literature for optimal management of acquired coagulopathy during and after LVAD
implantation is sparse. The traditional transfusion strategy of replacing coagulation factors with fresh frozen plasma involves the
risk of transfusion-associated circulatory overload. Current recommendations for targeted replacement of coagulation factors
with 4-factor prothrombin concentrate and fibrinogen concentrate in cardiac surgery may be translated in this special setting.
Summary The targeted, point-of-care use of concentrated coagulation factors may improve treatment of severe acquired coag-
ulopathy during LVAD implantation and in LVAD patients needing urgent non-cardiac surgery.
Keywords LVAD implantation . Cardiogenic shock . Coagulopathy . Bleeding . Re-exploration . Thromboelastometry .
Fibrinogen concentrate . 4-Factor prothrombin complex concentrate . Vitamin K antagonist reversal . von Willebrand disease .
Non-cardiac surgery
Introduction
The introduction of modern continuous flow rotary pump
systems into clinical practice facilitated the expansion of
the indication for implantation of left ventricular assist
devices (LVAD) from “bridge-to-transplantation” only to
“destination-therapy,” “bridge-to-recovery,” and “bridge-
to-decision” [1•]. This expansion of the indication result-
ed in a near linear increase of patients on LVAD support
over the last 15 years [1•]. It is well known that the im-
plantation of an LVAD system is associated with a highly
increased bleeding risk. This bleeding risk is reflected in
the huge amounts of blood products used. In a large US
database analysis, transfusions have been described to be
in the range of 15-20 units per surgical case [2]. Early re-
exploration due to persistent bleeding after LVAD im-
plantation occurs in 10-30% of patients [3] and is associ-
ated with increased mortality and morbidity [4]. Apart
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from the complexity of surgery, bleeding complications
may be attributed to a coagulopathy associated with the
underlying disease.
In this review, risk factors for perioperative bleeding com-
plications in LVAD patients are highlighted. The current ev-
idence for coagulation management during LVAD is present-
ed, and recommendations based on current guidelines and
consensus statements in the field of patient bloodmanagement
in cardiac surgery have been adapted for this specific medical
field. Strategies to treat acquired coagulopathy in LVAD pa-
tients needing urgent non-cardiac surgery or interventions are
discussed.
Coagulopathy and Management of Bleeding
During LVAD Implantation
Risk Factors for Increased Bleeding and Transfusion
During LVAD Implantation and Surgical Re-
Exploration
Current evidence is restricted to midsized observational stud-
ies. In a statewide US database analysis of 666 LVAD implan-
tations, urgent operation, re-do surgery, and preoperative use
of an intra-aortic balloon pumpwere associated with increased
transfusions [2]. A single-center investigation in 156 patients
identified preoperative mechanical ventilation, pre-implant
hemodialysis, and previous sternotomy as the primary risk
factors [5].
Two single-center studies assessed the risk factors for re-
operation due to persistent bleeding. In one study in 257 pa-
tients, concomitant implantation of a temporary right ventric-
ular assist device and destination therapy was independent risk
factors for early surgical revision [4]. In this study, the need
for surgical revision resulted in a clear trend (p=0.082) to-
wards increased early and mid-term mortality. Additionally,
the rates for postoperative renal replacement therapy (38.9%
vs. 12.9%) and stroke (36.1% vs. 8.8%) were significantly
increased in patients needing surgical revision due to bleeding
in comparison to patients without revision [4]. In a smaller
study in 83 patients, a low preoperative platelet count and
preoperative support with extracorporeal membrane oxygen-
ation therapy were identified as risk factors for surgical revi-
sion [6]. In two studies, the impact of re-do surgery on the
need for re-exploration after LVAD implantation was
assessed, but the results were conflicting [7, 8].
These data suggest that—apart from re-do surgery and co-
morbidities associatedwith the indication of “destination-ther-
apy”—there is a strong association between severity of the
cardiac disease and an increased risk of bleeding complica-
tions (Table 1). Such a concept is also supported by current
literature, which shows a close connection between the sever-
ity of heart failure and an effect on the coagulation system. In
chronic heart failure, there is an increase in coagulation factor
VII and VIII levels, fibrinogen, the von Willebrand factor,
platelet activity (tromboxane A2, platelet factor 4, and P-
selectin), and the D-dimers [9, 10]. In acute heart failure and
cardiogenic shock, the development of coagulopathy is a rare
complication but closely associated with an increased risk of
an adverse outcome.
In a single-center retrospective study in 160 patients, the
prevalence of coagulopathy as measured by the Japanese
Association of Acute Medicine disseminated intravascular co-
agulation score (JAAMDIC score) was 8%, and a score result
of ≥2 was independently associated with an increased all-
cause death rate (adjusted hazard ratio 2.5, p=0.005). Key
parameters of the JAAM DIC score are platelet count, pro-
thrombin time ratio, and fibrin degradation products [11]. In
another retrospective study of 10,004 patients admitted to a
single cardiac intensive care unit, the association of early car-
diovascular failure and non-cardiovascular organ failure (cen-
tral nervous system failure, coagulation failure, liver failure,
respiratory failure, and renal failure) and mortality was
assessed [12]. Organ failure was defined as a sequential organ
failure assessment (SOFA) sub-score ≥3 for the particular or-
gan system. The mortality risk was highest in patients with
cardiovascular and coagulation system or liver failure. The
prevalence of coagulation system and liver failure was rare
(<1%), but associated with a 2.9 and 4.0 adjusted odds ratio
(p<0.001).
In a large retrospective nationwide analysis of 444,253 pa-
tients with acute myocardial infarction and cardiogenic shock,
non-cardiac single and multiorgan failure (respiratory, hepat-
ic, renal, hematological, and neurologic) were diagnosed in
32.4% and 31.9% of patients. Hematologic failure, as defined
by secondary/unspecified thrombocytopenia, defibrination
syndrome, and acquired coagulation factor deficiency, oc-
curred in 5-15% of patients [13]. The odds ratio for hemato-
logical failure was 0.98 (95% CI 0.96-1.01). However, each
additional organ failure on top of cardiovascular failure was





• LVAD “destination therapy”
• Urgent surgery
• Preoperative mechanical ventilation
• Preoperative renal replacement therapy
• Preoperative thrombocytopenia
• Preoperative ECMO/ECLS or IABP
• Temporary RVAD
ECMO, extracorporeal membrane oxy-
genation; ECLS, extracorporeal life sup-
port system; IABP, intra-aortic balloon
pump; RVAD, right ventricular assist
device
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associated with a stepwise increase in the unadjusted and ad-
justed odds ratio for mortality [13].
Diagnosis and Treatment of Coagulopathy During
LVAD Implantation
We were unable to identify prospective or larger retrospective
studies specifically addressing coagulation management dur-
ing LVAD implantation. Data are limited to one small retro-
spective study, which evaluated the safety of a 3-factor pro-
thrombin complex concentrate (PCC) in this setting [14].
However, the major contributors to coagulopathy in the pa-
tient with severe heart failure needing LVAD implantation are
defined (Table 2). Therefore, diagnostic and therapeutic strat-
egies derived from current cardiac surgery blood management
guidelines and consensus statements may be applied to this
specific condition.
Hyperfibrinolysis
Cardiac failure can be associated with disseminated intra-
vascular coagulation. Additionally, cardiopulmonary by-
pass (CPB) leads to a massive activation of the fibrinolyt-
ic system [15]. The lysine analog tranexamic acid (TXA)
is a potent inhibitor of fibrinolysis. A recent meta-analysis
of RCTs showed that TXA effectively reduced transfusion
requirements in cardiac surgery [16]. However, particular-
ly in cardiac surgery, TXA has been associated with an
increased risk of convulsive seizures [17]. This risk is
dose-dependent and especially elevated in open-heart sur-
gery [17].
A recent systematic review showed that TXA concentra-
tions of 10-15 mg/ml result in substantial inhibition of fibri-
nolysis [18]. Established low-dose protocols for TXA (bolus
of 10 mg/kg, continuous infusion of 1 mg/kg/h during CPB
and 1 mg/kg in the CPB prime) achieve concentrations of
approximately 30-50 mg/ml [19] and have been shown to be
as effective as high-dose protocols to reduce blood loss in
cardiac surgery [16]. Therefore, TXA should be considered
during LVAD implantation to reduce hyperfibrinolysis.
However, when using TXA, a low-dose protocol should be
preferred to reduce the risk of TXA-associated convulsive
seizures.
Platelets
Platelets contribute to clot formation via adhesion, aggrega-
tion, and activation of coagulation factors, which stabilize the
initial platelet plug in the injured tissue [20]. Platelet effective-
ness in this regard depends on both platelet function (ability to
be activated or aggregate) and platelet number. According to
current guidelines, in the bleeding patient undergoing cardiac
surgery, a platelet count below 50 × 109/l is defined as the
trigger value for the transfusion of platelet concentrates [20,
21]. As an alternative to the platelet count, viscoelastic tests
(e.g., rotational thromboelastometry) may be used. The max-
imal clot firmness (MCF) in the extrinsically activated assay
(ExTEM) may be used [22]. This value demonstrated a good
correlation with critical platelet count values, and as the assay
is insensitive to heparin concentrations < 4 IU/ml, sampling
can even be performed during CPB. As theMCF also depends
on fibrinogen concentration, it is advisable to perform a
FibTEM test in parallel in order to estimate the actual fibrin-
ogen concentration and rule out that the MCF is largely affect-
ed by fibrinogen [22, 23]. However, in patients who are re-
ceiving antiplatelet therapy, platelet transfusion may be indi-
cated even when platelet counts are higher than 50 × 109/l. Of
note, viscoelastic tests are not sensitive for detecting a platelet
function defect caused by antiplatelet therapy. Modern assays
such as light transmission aggregometry in whole blood pro-
vide a rapid tool to assess the effect of antiplatelet agents such
as aspirin or clopidrogrel on platelet activation [24]. In these
patients, preoperative assessment of the antiplatelet effect may
help to decide if platelet concentrates should be transfused
even when platelet numbers are above 50 109/l or the
ExTEM MCF is in the reference range.
Fibrinogen
Fibrinogen plays a central role in the coagulation cascade in
which thrombin-mediated conversion of fibrinogen to fibrin is
the final step [25]. However, fibrinogen also facilitates platelet
aggregation by cross-linking platelets via their glycoprotein
IIb/IIIa receptor. In the case of hypofibrinogenemia, fibrino-
gen may be replaced by transfusion of cryoprecipitate, which
also contains von Willebrand factor, factor VIII and factor
XIII, or by the transfusion of fibrinogen concentrate. The
supporting evidence for transfusion of concentrated fibrino-
gen in cardiac surgery is weak. However, a recent consensus
statement thoroughly reviewed this topic and provided prag-
matic recommendations for the use of fibrinogen concentrate
in the bleeding cardiac surgery patient [26••].
Usually, fibrinogen is monitored via standard laboratory
tests, but there are doubts that the tests provide reliable results
after weaning fromCPB and in the presence of larger amounts
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• Hyperfibrinolysis
• Hypofibrinogenemia
• Acquired coagulation factor deficiency
78 Curr Anesthesiol Rep  (2021) 11:76–83
surgery, monitoring of fibrinogen via viscoelastic tests, such
as FibTEM, has been proposed [26••].
According to a recent European consensus statement,
transfusion of fibrinogen concentrate is strongly recommend-
ed in patients with microvascular bleeding and a FibTEM
MCF of < 4-6 mm and may be considered if FibTEM values
are 6-8 mm [26••]. Transfusion of fibrinogen concentrate
should target FibTEM values > 9 mm, whereas FibTEM
values > 14 mm should be avoided. As 1 g of fibrinogen
concentrate increases the FibTEM MCF by approximately
2 mm (or 0.2-0.3 g/l in the standard Clauss fibrinogen test),
calculation of the necessary dose to achieve target values is
easy to perform [26••]. When using standard laboratory tests,
the target concentration may be defined in the range of 1.5-2
g/l [26••]. Alternatively, cryoprecipitate may be transfused,
which raises the fibrinogen concentration by 1 g/l when two
units are given for each 10 kg of bodyweight [26••].
Acquired Coagulation Factor Deficiency
Traditionally, an acquired coagulation factor deficiency is
treated with transfusion of fresh frozen plasma (FFP).
However, large volumes exceeding 15-30 ml/kg are needed
to achieve target coagulation factor levels. In this regard, par-
ticularly in patients with impaired left or right ventricular
function, the risk of transfusion-associated circulatory over-
load (TACO) is a limiting factor.
Modern 4-factor PCCs, which contain the coagulation fac-
tors II, VII, IX, and X, are increasingly used, not only for
reversal of Vitamin K antagonist (VKA) therapy but also for
“hemostatic resuscitation” of the massively bleeding patient
[27]. The advantages of this therapeutic approach are obvious:
quick reconstruction of the lyophilized concentrates and an
immediate effect achieved by the transfusion of small volumes
(20 ml = 500 IU PCC).
Current data on the use of PCC during LVAD implantation
are limited to a smaller retrospective safety study in which a 3-
factor PCC, which does not contain the coagulation factor VII,
was used [14]. The study included 41 patients who received the
PCC due to excessive bleeding during LVAD implantation and
21 patients who did not receive the PCC. No risk adjustment was
performed. PCC was dosed in increments of 500 IU every 30
minutes until adequate hemostasis was achieved. The maximum
dose according to the protocol was 25 IU/kg. The overall inci-
dence of thromboembolic events was 29.3% in the PCC group
and 22.2% in the non-PCC group (p>0.05).
Modern 4-factor PCCs contain larger amounts of coagulation
factor VII. Although they have been used for decades, particu-
larly in Europe, they have been introduced in the United States
only recently. However, despite their increased use, evidence of
drug efficacy and particularly of drug safety is low. Reports of
severe thromboembolic events overshadow reports of successful
PCC use in the massively bleeding patient.
A recently published European consensus statement pro-
vided a comprehensive review of the available evidence and
recommendations for the use of modern 4-factor PCC in trau-
ma and in the perioperative setting of cardiac surgery [28••].
According to this statement, a dose of 25 IU/kg 4-factor PCC
is considered as standard for both VKA reversal and “hemo-
static resuscitation.” However, the authors highlighted the
lack of adequate safety data. Therefore, in patients with a high
thromboembolic risk, such as in cardiac surgery, a stepwise
approach to the use of 4-factor PCC is recommended.
According to the referenced consensus statement, for both
indications -VKA reversal and “hemostatic resuscitation”—a
bolus of 12.5 IU/kg of a 4-factor PCC is recommended in the
massively bleeding patient with coagulopathy [28••]. A sec-
ond bolus may be given if coagulopathy and microvascular
bleeding persist and other reasons for bleeding are largely
ruled out [28••]. Moreover, tissue-factor-activated coagulation
tests, which are sensitive to coagulation factor VII, such as the
prothrombin time or international normalized ratio (INR), or
point-of-care (POC) tests—such as the ExTEM—may be used
to guide coagulation therapy with 4-factor PCC [28••].
A Practical Approach toManage Coagulopathy During
LVAD Implantation (Fig. 1)
Preoperative assessment of the coagulation system includes
platelet count, INR, and the activated partial thromboplastin
time. However, particularly in Interagency Registry of
Mechanically Assisted Circulatory Support (INTERMACS)
profile 1 patients (critical cardiogenic shock is present), addi-
tional determination of fibrinogen concentration and D-dimers
appears to be helpful to assess the severity of a potential pre-
operative coagulopathy. In the case of actual antiplatelet ther-
apy, assessment of platelet function via aggregometry is help-
ful to evaluate the effect of these agents on platelet activation.
In all patients, low-dose TXA is given to inhibit ongoing and
CPB-associated hyperfibrinolysis. Modern viscoelastic point-
of-care systems, such as thromboelastometry, provide quick
insight into the current status of the coagulation system and
help guide targeted transfusion therapy [27, 29].
Approximately 20 minutes before the planned weaning from
extracorporeal circulation (CPB or extracorporeal life support
system), thromboelastometry with an ExTEM and FibTEM
assay is performed [27, 29]. These tests are complementary
[22, 23] and will provide helpful information about the platelet
count, fibrinogen concentration, and status of the plasmatic
coagulation factors. In the bleeding patient, a FibTEM MCF
of 8-10 mm should be sought [30]. The evaluation of the
platelet count is performed by calculating the difference be-
tween the ExTEMMCF and FibTEM MCF. The target value
is >30 mm [23]. In the case of preoperative dual antiplatelet
therapy and responsiveness of the platelets in platelet
aggregometry, platelet concentrates are transfused even if
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the ExTEM−FiTEMMCF value is in the target range. In case
of moderate prolongation of the ExTEM CT (approximately
80-100 seconds; reference value <80 seconds), approximately
15-20 ml/kg of FFP are transfused [30]. In case of a more
prolonged value of the ExTEM CT (>100 seconds), 12.5 IU/
kg (nearest vial content) of a 4-factor PCC is given [30]. A
second bolus of 12.5 IU/kg PCC is given if bleeding persists.
The fast bloodstream velocity and shear stress achieved
by contemporary laminar flow LVADs lead to the
unfolding of the von Willebrand factor, with disruption
of the high-molecular-weight multimers into smaller, less
hemostatic multimers [31•]. Although there is no current
evidence about intraoperative treatment of this acquired
von Willebrand disease (type 2A), desmopressin is given
in the case of persisting microvascular bleeding, with a
dose of 0.3-0.4 μg/kg bodyweight to promote release of
von Willebrand factor from the cellular storage sites. If
microvascular bleeding stops and the patient still requires
infusion of larger fluid volumes, FFP may be transfused to
maintain the status of the coagulation factors. However, in
the case of persistent diffuse microvascular bleeding but
normal values in the coagulation tests, secondary chest
closure after 12-24 hours may be a viable option [32].
Coagulopathy and Management of Bleeding
for Non-Cardiac Surgery in LVAD Patients
Acquired Coagulopathy in LVAD Patients
Particularly in LVAD patients, the delicate anticoagulation bal-
ance between the risks of bleeding and thromboembolic events is
hard to achieve [33••]. Both complications are frequent in this
patient population [33••]. The acquired coagulopathy of LVAD
patients is a result of antiplatelet therapy, VKA therapy, and the
shear stress induced by vonWillebrand disease [33••]. Aspirin is
usually given for antiplatelet therapy, at a dose between 81 mg
and 325 mg [33••]. Vitamin K antagonist therapy is guided via
the INR, which is usually maintained between 1.5 and 3 [33••].
However, in contrast to other patient populations, such as patients
with atrial fibrillation, LVAD patients spend less time out of the
INR target range [33••]. Infections in particular appear to have a
huge impact on INR deregulation and concomitant bleeding
complications [34]. As outlined before, the fast bloodstream
leads to shear stress-induced unfolding of the complex von
Willebrand protein and excessive cleavage of the high molecular
multimers by metalloprotease ADAMTS-13 in the LVAD cir-
cuit. The von Willebrand factor plays an important role in the
Fig. 1 Suggested algorithm for the management of coagulopathy during
LVAD implantation. aPTT, activated partial thromboplastin time; INR,
international normalized ratio; INTERMACS, Interagency Registry of
Mechanically Assisted Circulatory Support; EEE, extracorporeal
circulation; MCF, maximal clot firmness; CT, coagulation time; FFP,
fresh frozen plasma; PCC, prothrombin complex concentrate
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complex interaction of the endothelium and platelets. Moreover,
the von Willebrand factor carries and protects coagulation factor
VIII from enzymatic cleavage. Of note, this domain of the von
Willebrand factor appears not to be affected by the shear stress,
as activated partial thromboplastin time values are usually within
the reference range. However, this acquired qualitative defect of
this complex protein is hard to diagnose, even with a sophisticat-
ed pattern of specific laboratory tests, and its use is still contro-
versial [33••].
Urgent Non-Cardiac Surgery in LVAD Patients
In a large national retrospective investigation in 30,232 pa-
tients on LVAD, 3216 non-cardiac surgical procedures were
performed [35]. Surgery was urgent in 73.5% of interventions,
and urgent/emergency surgery was highly predictive for an
increased mortality (OR 3.1, 95% CI 1.9-5). The in-hospital
mortality was 7.7% and highest in neurologic surgery, while
vascular surgery had the highest rates of stroke. Transfusions
were necessary in 42.5% of patients.
Management of Bleeding in LVAD Patients
Undergoing Non-Cardiac Surgery
In the LVAD patient who needs urgent non-cardiac surgery, the
acquired coagulopathy might need a targeted treatment. In this
condition, transfusion of platelets and replacement of coagulation
factors is recommended [35]. The replacement of coagulation
factors can be achieved via the transfusion of FFP or 4-factor
PCC. Modern 4-factor PCC is designed for targeted reversal of
oral anticoagulation with VKA. The experience in LVAD pa-
tients is limited to a few small retrospective single-center studies
[36]. Dosages of the 4-factor PCC varied between 10 and 30 IU/
kg. In all cases, the INR was effectively decreased to enable
surgery or to provide effective hemostasis. No thromboembolic
events were reported [35]. However, the thromboembolictic risk
when using PCC is generally acknowledged, and numbers are
too small to provide general recommendations [28••]. The role of
treatment of diffuse microvascular bleeding in the LVAD patient
with desmopressin or von Willebrand factor concentrate is still
unclear and is restricted to anecdotal reports [37••, 38, 39].
Viewing the pathomechanism of the von Willebrand disease in
LVADpatients, the effect of endogenously released or transfused
von Willebrand factor will only persist for few minutes [30].
Therefore, these approaches need further evaluation before being
implemented in clinical practice.
Conclusions
The implantation of LVAD systems is associated with bleeding
complications and surgical re-exploration rates which apparently
impact clinical outcomes. The severity of the preoperative
disturbances of the coagulation system appears to be directly
related to the severity of the cardiac failure. In the current litera-
ture, evidence for perioperative coagulation management in pa-
tients undergoing LVAD implantation is sparse. However, cur-
rent guidelines and consensus statements provide useful informa-
tion about how to manage coagulation system failure in cardiac
surgery. The use of an antifibrinolytic agent such as TXA and
transfusion of platelets is standard practice in complex cardiac
surgery. However, the “classical” transfusion strategy—
involving replacement of coagulation factors with FFP—
involves the risk of TACO. This is of particular importance in
patients with impaired right ventricular function. Based on the
results of thromboelastometry, the targeted use of 4-factor PCC
and fibrinogen concentrate deserves special attention, as rapid
replacement of coagulation factors is achieved with the transfu-
sion of low volumes. In the patient with an LVAD, the coagula-
tion system is affected by antiplatelet therapy, VKA therapy, and
acquired von Willebrand disease. In the LVAD patient who
needs urgent non-cardiac surgery, the transfusion of 4-factor
PCC appears to be an effective strategy for quick reversal of
VKA therapy. However, the potential risk for thromboembolic
complications (e.g., pump thrombosis) has to be kept in mind.
The use of desmopressin or vWF concentrates to treat the
LVAD-associated von Willebrand disease, and coagulopathy
needs further evaluation.
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